2019
Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough?
Gubitosi‐Klug R, Bebu I, White NH, Malone J, Miller R, Lorenzi GM, Hainsworth DP, Trapani VR, Lachin JM, Tamborlane WV, Group* F. Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough? Pediatric Diabetes 2019, 20: 743-749. PMID: 31206973, PMCID: PMC7217664, DOI: 10.1111/pedi.12877.Peer-Reviewed Original ResearchConceptsYears of ageType 1 diabetesDiabetic retinopathyEye examEarly Treatment Diabetic Retinopathy Study (ETDRS) scaleMild non-proliferative diabetic retinopathyDiabetic Retinopathy Study scaleNon-proliferative diabetic retinopathyDiabetic retinopathy assessmentDiabetic retinopathy statusBaseline glycated hemoglobinClinical trial evidenceSignificant macular edemaProliferative diabetic retinopathyStandardized clinical trialsDiabetic retinopathy examinationsRetinopathy assessmentRetinopathy statusBaseline characteristicsComplications TrialMacular edemaCase seriesDiabetes controlIncident casesTrial evidenceBiologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network
McGill JB, Wu M, Pop-Busui R, Mizokami-Stout K, Tamborlane WV, Aleppo G, Gubitosi-Klug RA, Haller MJ, Willi SM, Foster NC, Zimmerman C, Libman I, Polsky S, Rickels MR. Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network. Journal Of Diabetes And Its Complications 2019, 33: 107400. PMID: 31279735, DOI: 10.1016/j.jdiacomp.2019.06.005.Peer-Reviewed Original ResearchConceptsAdverse kidney outcomesDiabetic kidney diseaseKidney outcomesType 1 diabetesKidney diseaseRisk factorsRisk of DKDDevelopment of DKDT1D Exchange Clinic NetworkAlbumin/creatinine ratioIncident kidney diseaseBlood pressure controlModifiable risk factorsT1D Exchange RegistryUrine albumin measurementsLow education levelModern clinical practiceEGFR declineIncident albuminuriaT1D durationBaseline characteristicsSerum creatinineCreatinine ratioMajor complicationsHigher HbA1c
2010
Characteristics of Adolescents and Youth with Recent-Onset Type 2 Diabetes: The TODAY Cohort at Baseline
Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, Pyle L, Tamborlane W, Willi S. Characteristics of Adolescents and Youth with Recent-Onset Type 2 Diabetes: The TODAY Cohort at Baseline. The Journal Of Clinical Endocrinology & Metabolism 2010, 96: 159-167. PMID: 20962021, PMCID: PMC3038479, DOI: 10.1210/jc.2010-1642.Peer-Reviewed Original ResearchConceptsType 2 diabetesBlood pressureFamily historyBiochemical abnormalitiesRecent-onset type 2 diabetesLow high-density lipoprotein levelsRecent-Onset Type 2Body mass index z-scoreHigh-density lipoprotein levelsDiabetes care clinicMean diabetes durationYr of diagnosisTODAY cohortBody mass indexIndex z-scoreNon-Hispanic blacksLow socioeconomic statusBaseline data collectionParents/guardiansDiabetes durationBaseline characteristicsHigh triglyceridesCare clinicsLipoprotein levelsMass indexSTAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects
Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects. Diabetes Technology & Therapeutics 2010, 12: 249-255. PMID: 20210562, PMCID: PMC2883476, DOI: 10.1089/dia.2009.0145.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous subcutaneous insulin infusionType 1 diabetesPercentage of subjectsPump therapyEnd pointBaseline characteristicsDaily injectionsKey safety end pointsType 1Sensor-Augmented Pump TherapyReal-time continuous glucose monitoringSensor-Augmented Insulin Pump TherapyNormal glycemic rangeTertiary end pointPrimary end pointSafety end pointSecondary end pointsInsulin pump therapySubcutaneous insulin infusionYears of treatmentContinuous glucose monitoringMDI cohortSevere hypoglycemiaClinical outcomes